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Hepatitis C Infection and Metabolic Syndrome
Ching-Sheng Hsu,1,2 Jia-Horng Kao2−5*
Infection with the Hepatitis C virus (HCV) is a
globally important cause of chronic hepatitis, cir-
rhosis and hepatocellular carcinoma.1,2 HCV in-
fection is also associated with several extrahepatic
manifestations, including mixed cryoglobuline-
mia, non-Hodgkin lymphoma, porphyria cutanea
tarda, lichen planus, thyroid disease (usually hypo-
thyroidism), lymphocytic sialadenitis, and poly-
arthritis.3 Among extrahepatic diseases, metabolic
derangements of patients with chronic HCV in-
fection have been increasingly recognized and
have become an area of active investigation, espe-
cially given the global epidemic of obesity and
diabetes. Although a direct link between obesity or
metabolic syndrome and HCV infection remains
unclear,4 several studies have demonstrated syn-
ergistic effects of HCV infection and obesity on the
development of liver cancer.5 Accumulating evi-
dence already demonstrates that HCV infection
has an impact on metabolic derangements, includ-
ing glucose metabolism and lipid metabolism.6–10
It is thus reasonable to speculate that HCV itself
may elicit liver cell damage as well as metabolic
abnormalities. Both events will lead to the emer-
gence and progression of metabolic syndrome.
The interactions between HCV infection and
metabolic syndrome are reviewed and discussed
in this article.
HCV Infection and Glucose Metabolism
Epidemiological studies have demonstrated a
higher prevalence of HCV infection in diabetic pa-
tients compared with matched controls,6 a higher
prevalence of diabetes in HCV-infected patients,6,8
and an increased risk of developing diabetes in pa-
tients infected with HCV than those not infected
[relative hazard = 11.58; 95% confidence interval
(CI) = 1.39–96.6].11 Of particular note is that a
population-based survey on 10,975 Southern
Taiwanese participants identified a significant link
between type 2 diabetes mellitus and HCV viremia.
The prevalence of type 2 diabetes mellitus in HCV
viremic subjects (18.0%) was significantly higher
than those in hepatitis B surface antigen (HBsAg)-
positive subjects (11.4%) and subjects negative for
both viral hepatitis markers (12.5%).12 Moreover,
HCV infection may induce insulin resistance (IR),
and this effect seems to be genotype-specific with
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a lower IR in genotype 3 than other genotypes.13
Our previous studies on Taiwanese chronic hep-
atitis C patients not only identified an association
between higher HCV RNA level and a lower serum
adiponectin level, a marker of IR,14 but also a
dose-dependent response between homeostatic
model assessment-IR index (a method of IR mea-
surement) and HCV RNA level. 15 These findings
have been confirmed by a recent study.16
Several mechanisms have been proposed to
explain the relationship between HCV infection,
IR and diabetes, such as a direct pancreatic β cell
destruction, autoimmune β cell injury, and the
presence of non-alcoholic fatty liver disease.17
One study examined the liver specimens from
non-obese and non-diabetic subjects with HCV
infection and found that HCV infection may
contribute to IR by causing an insulin signaling
defect in hepatic insulin receptor substrate (IRS)-
1 tyrosine phosphorylation and phosphatidyli-
nositol 3-kinase activation.18 In addition, studies
on HCV core-transgenic mice livers and HCV core-
transfected human hepatoma cells demonstrated
that HCV may regulate glucose metabolism by
core-induced suppression of cytokine signal 3 as
well as the promotion of proteasomal degrada-
tion of IRS-1 and IRS-2 through ubiquitination.19
Elevated tumor necrosis factor-alpha level with dis-
turbance in tyrosine phosphorylation of IRS-1,20
or expression of protein phosphatase 2A to de-
phosphorylate protein kinase B/Akt have also been
indicated.21 Conversely, despite the small sequence
divergence of the HCV core proteins of genotypes
3a and 1b, these two proteins appear to interfere
with the insulin signaling pathway by different
and genotype-specific mechanisms (Figure).22
HCV Infection and Lipid Metabolism
Hepatic steatosis is commonly observed in subjects
with chronic HCV, occurring in approximately
50% of liver biopsy samples, with a reported range
of 30–70%.8,14,23,24 A comparison study between
317 HCV liver biopsy specimens and 299 hepati-
tis B viral specimens indicated that large-droplet
fat is more likely to be seen in HCV than in hep-
atitis B viral infection (OR = 2.4; 95% CI =
1.4–4.1), and Mallory body-like material is found
only in HCV biopsy specimens (OR = 71.6; 95%
CI = 4.4–996.1).24 Regarding liver histologic data
among patients with different HCV genotype in-
fections, genotype 3a infection has a significantly
higher prevalence of steatosis.9,25 In addition,
the grade of hepatic steatosis is associated more
with HCV RNA level in genotype 3a infection
(r=0.786; p< .001), but less with body mass index
in genotype 1 infection (r=0.689; p< .001).9 How-
ever, existing lines of evidence indicate a combi-
nation of host and viral effects on steatosis, with
the relative importance of each varying with HCV
genotype.26,27 In Taiwan, HCV genotypes 1 and 2
are more rampant than other genotypes, and he-
patic steatosis in chronic hepatitis C patients was
found to be associated with features of metabolic
syndrome, rather than HCV genotype, advanced
fibrosis or the response to antiviral therapy.10 The
link between HCV and metabolic abnormalities
is further supported by two population-based
studies from Taiwan, one showed an association
between positive anti-HCV and serum high-density
lipoprotein-cholesterol level as well as serum tri-
glyceride level,28 and the other demonstrated lower
serum cholesterol and triglyceride levels in HCV
viremic patients.29 Furthermore, our recent data
identified that chronic hepatitis C patients not only
have higher high-density lipoprotein-cholesterol,
lower total cholesterol, triglyceride, and low-
density lipoprotein-cholesterol (LDL) levels, but
also higher serum adiponectin levels than matched
healthy controls.7 Conversely, sustained disap-
pearance of HCV is associated with reduction of
steatosis in genotype 3,30 and a correction of base-
line low serum cholesterol and LDL.27,31 A recent
study confirmed that HCV infection was associ-
ated with decreased cholesterol and LDL levels
and this hypolipidemic effect disappeared with
successful hepatitis C treatment but persisted in
non-responders.31 Additionally, a significant por-
tion of patients successfully treated had rebound
LDL and cholesterol to levels associated with 
increased risk of coronary heart disease.
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The mechanisms involved in the association
of hepatic steatosis with HCV infection remain
unclear.32 Evidence from transgenic murine mod-
els showed that expression of HCV structural
proteins enhances a low background of hepatic
steatosis,33 and HCV core protein may inhibit
microsomal triglyceride transfer protein activity,
very low density lipoprotein secretion,34 as well
as alter the expression patterns of lipid metabo-
lism genes.35 Recent studies further identified the
important roles of HCV core and NS5A protein
on HCV-induced dyslipidemia and steatosis.36−39
Moreover, experiments have demonstrated the
important roles of assembly and secretion of very
low-density lipoproteins in HCV production,40
and using inhibitors of lipid metabolism may
suppress replication of infectious HCV clones.41
Of particular note, the lipid droplet, an organelle
for the storage of neutral lipids, has been linked
to the production of infectious virus particles,42
which implies a linkage between HCV RNA lev-
els and lipid profiles. We thus assessed this possi-
ble link in 531 chronic hepatitis C patients, and
found a proportional relationship between serum
lipid profiles and hepatitis C viral load in patients
with genotype 2 infection, but not in genotype 1
infection.43
Effects of Metabolic Abnormalities on
HCV Infection
In addition to the impact of HCV infection on
metabolic profiles, metabolic abnormalities may
influence disease progression and therapeutic re-
sponse in chronic hepatitis C patients. Several


















Figure.Hepatitis C virus affects signal transduction of insulin. The insulin receptor is tyrosine kinase-linked and undergoes auto-
phosphorylation. This receptor catalyses the phosphorylation of cellular proteins such as insulin receptor substrate (IRS)-1 or
2. Upon tyrosine phosphorylation, these proteins interact with signaling molecules, resulting in a diverse series of signaling
pathways, including activation of phosphatidylinositol-3-OH kinase and downstream PtdIns(3,4,5)P3-dependent protein ki-
nases (PIP3-dependent protein kinases), such as phosphoinositide-dependent kinase 1 (PDK1) or atypical protein kinase C.
PIP3 interacts with and activates PDK1, which partially activates protein kinase B (PKB) by phosphorylating PKB at Thr308.
Maximal activation of PKB also requires the phosphorylation of Ser473 by mammalian target of rapamycin (mTOR) complex.
These pathways act in concert to coordinate the regulation of glucose, lipid and protein metabolism. Hepatitis C virus (HCV)
may affect these pathways by core-induced suppression of cytokine signal 3, as well as the promotion of proteasomal degra-
dation of IRS-1 and IRS-2 through ubiquitination. Alternatively, HCV may elevate tumor necrosis factor-alpha (TNF-α) levels
disturbing tyrosine phosphorylation of IRS-1, or expression of protein phosphatase 2A (PP2Ac) to dephosphorylate PKB/Akt.
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studies have shown a significant and independent
association between the grade of steatosis and
liver fibrosis,44 as well as IR and fibrotic progres-
sion in chronic hepatitis C.13 Meanwhile, obesity,
defined as a body mass index greater than 30 kg/
m2, is a negative predictor of response to hepatitis
C treatment, independent of genotype and cirrho-
sis.45 Similarly, a higher IR is associated with a
lower sustained virologic response in patients
treated with combination therapy of peginterferon
plus ribavirin,46,47 especially among a “difficult-
to-treat” population.48 A study evaluating 198
chronic hepatitis C patients treated with combi-
nation therapy showed that HCV genotype 1b
virus may induce IR via up-regulation of sup-
pressor of cytokine signal 3 to impair therapeutic
response (OR = 6.7; p < 0.005).19,49 Conversely,
clearance of HCV appears to improve IR, β cell
function and hepatic IRS-1/2 expression.50
Conclusions
HCV induces several metabolic abnormalities as
well as interacts with the components of meta-
bolic syndrome. These interactions vary among
different HCV genotypes. In addition, each 
component of metabolic syndrome can directly
influence the other, and thus all components
should be managed simultaneously to delay or
prevent disease progression and to improve ther-
apeutic response in patients with chronic HCV 
infection.
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